A detailed history of Bank Of America Corp transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Bank Of America Corp holds 4,653,325 shares of ADAP stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,653,325
Previous 4,653,325 -0.0%
Holding current value
$2.75 Million
Previous $4.56 Million 3.07%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.83 - $1.47 $12,003 - $21,259
-14,462 Reduced 0.31%
4,653,325 $4.56 Million
Q1 2024

May 15, 2024

SELL
$0.7 - $1.75 $21,116 - $52,792
-30,167 Reduced 0.64%
4,667,787 $7.38 Million
Q4 2023

Feb 14, 2024

SELL
$0.43 - $0.79 $199 - $367
-465 Reduced 0.01%
4,697,954 $3.71 Million
Q2 2023

Aug 14, 2023

SELL
$0.9 - $1.51 $632,961 - $1.06 Million
-703,291 Reduced 13.02%
4,698,419 $4.32 Million
Q1 2023

May 12, 2023

BUY
$1.06 - $2.16 $702,883 - $1.43 Million
663,098 Added 13.99%
5,401,710 $5.89 Million
Q4 2022

Feb 10, 2023

BUY
$1.05 - $2.53 $3.89 Million - $9.37 Million
3,703,418 Added 357.75%
4,738,612 $6.92 Million
Q3 2022

Nov 14, 2022

BUY
$1.06 - $2.41 $46,375 - $105,437
43,750 Added 4.41%
1,035,194 $1.11 Million
Q2 2022

Aug 12, 2022

BUY
$1.33 - $2.28 $621,418 - $1.07 Million
467,232 Added 89.13%
991,444 $1.69 Million
Q1 2022

May 16, 2022

SELL
$1.73 - $4.06 $24,045 - $56,429
-13,899 Reduced 2.58%
524,212 $1.08 Million
Q4 2021

Feb 08, 2022

SELL
$3.5 - $5.68 $678,944 - $1.1 Million
-193,984 Reduced 26.5%
538,111 $2.02 Million
Q3 2021

Nov 15, 2021

BUY
$3.44 - $6.37 $2.47 Million - $4.58 Million
719,108 Added 5537.14%
732,095 $3.79 Million
Q2 2021

Sep 13, 2021

BUY
$3.86 - $5.78 $50,129 - $75,064
12,987 New
12,987 $55,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $96.4M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.